Information Provided By: 
Fly News Breaks for January 16, 2018
TSRO, HRTX
Jan 16, 2018 | 08:41 EDT
Mizuho analyst Difei Yang notes that Tesaro (TSRO) announced a modification to the Warning section in the prescribing information of Varubi IV - a direct competitor to Cinvanti - following a high rate of anaphylaxis associated with the drug. The analyst sees this development as potentially very positive for Heron Therapeutics (HRTX) given the strong safety profile of Cinvanti in clinical studies. Yang reiterates a Buy rating and $28 price target on Heron's shares.
News For HRTX;TSRO From the Last 2 Days
HRTX
Apr 26, 2024 | 10:52 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Heron Therapeutics (HRTX),... To see the rest of the story go to thefly.com. See Story Here
HRTX
Apr 25, 2024 | 10:38 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
